SM
OREX

Sabby Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Sabby Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-226
Closed -$1.27M – 320
2013
Q4 		$1.27M Sell
226
-383
-63% -$21.5K 0.08% 103
2013
Q3 		$3.74M Sell
609
-151
-20% -$10.2K 0.24% 62
2013
Q2 		$4.45M Buy
+760
New +$46.8K 0.3% 65

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
GL
GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Sabby Management's OREX Position: Q4 2017 in Review

Sabby Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2017, closing a stake of 19,700 shares — an estimated $42K sold.

Sabby Management first reported a position in OREX in Q1 2014 and held it in 4 quarters. The position peaked at $309K in Q2 2014. 41 funds tracked by Wall St. Rank hold OREX as of Q4 2017.

  • Sabby Management reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Sabby Management sold 19,700 Orexigen Therapeutics, Inc. shares in Q4 2017, an estimated $42K.
  • Sabby Management first reported a position in Orexigen Therapeutics, Inc. in Q1 2014 and held it in 4 quarters.
  • Sabby Management's Orexigen Therapeutics, Inc. position peaked at $309K in Q2 2014.
  • 41 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2017.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.